Please upgrade your browser.
The drug would also be the first in a new class of immune- boosting medicines able to treat an array of tumors. Anti-PD-1, shrunk or stabilized tumors in 8 of 16 kidney cancer patients, researchers reported at a medical conference earlier this year.
The outcome of patients with metastatic renal cell carcinoma has been substantially improved with administration of the currently available molecularly targeted therapies. However, proper selection of therapy and management of toxicities remain challenging. NCCN convened a multidisciplinary task force panel to address the clinical issues associated with these therapies in attempt to help practicing oncologists optimize patient outcomes.
Many of the therapies used to treat advanced kidney cancer and prevent renal failure are biologic medications. Patient safety is a high priority.
The PREDICT research consortium will screen the entire gene set in kidney cancer patients to identify which genes regulate cancer cell growth in a low oxygen environment.
Some politicians want to punish America's charities by balancing the federal budget on the backs of our nation's most vulnerable citizens. Stop the insanity. Take action now!
|Powered by NeonCRM|